Skip to main content

Recent News & Research

ResearchTreatments

Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers

*January 2022* Highlights: p53 and Rb alterations are confirmed as predisposing to SCLC transformation in EGFR- LUAD. Paired EGFR-LUAD/SCLC samples showed diverse clonal evolution patterns. TERT amplification is an acquired event during EGFR-LUAD to SCLC transformation. Introduction Among the different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs)…
laurabbook@gmail.com
March 18, 2022
ResearchTreatments

Research Articles on HER2 and Exon 20 Mutations in NSCLC

*March 2022* Human Epidermal Growth Factor Receptor 2–Mutant Non–Small-Cell Lung Cancer: Continued Progress But Challenges Remain Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial FDA Grants Breakthrough Therapy Designation to DZD9008 for EGFR Exon20Ins-Positive NSCLC
laurabbook@gmail.com
March 18, 2022
ResearchTreatments

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence

*January 2022* Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. We conducted a systematic review to investigate the available data on this patients’ subgroup. Overall, we found a high heterogeneity in the incidence of compound mutations (4–26% of…
laurabbook@gmail.com
March 18, 2022
ResearchTreatments

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients

*January 2022* Highlights Clonal architecture of molecular alterations at the cellular level depicts cancer cell adaptation during targeted therapy. Single cell sequencing from patient biopsies revealed the co-existence of two driver alterations within single cancer cells. Pharmacological evaluation in patient derived models asserts the need of simultaneous inhibition of each driver. Read…
laurabbook@gmail.com
March 18, 2022
ResearchTreatments

Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Enhertu in HER2-Mutant NSCLC

*December 2021* NEW YORK – Daiichi Sankyo and AstraZeneca on Thursday said that the first patient with HER2-mutant advanced non-small cell lung cancer has received treatment in a Phase III trial comparing their antibody-drug conjugate trastuzumab deruxtecan (Enhertu) against an immunotherapy-chemotherapy combination in the first-line setting. The DESTINY-Lung04 trial is evaluating trastuzumab…
laurabbook@gmail.com
March 16, 2022